[{"id":"ea26acb5-1d9c-43f2-bde5-b6e08ca13bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554939","created_at":"2022-09-26T14:56:16.908Z","updated_at":"2025-02-25T14:09:09.767Z","phase":"Phase 1/2","brief_title":"Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL","source_id_and_acronym":"NCT05554939","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14)","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/11/2022","start_date":" 12/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"6358176d-fc44-4d02-9e47-56116f950879","acronym":"","url":"https://clinicaltrials.gov/study/NCT00574496","created_at":"2021-01-18T02:05:52.845Z","updated_at":"2024-07-02T16:35:35.650Z","phase":"Phase 2","brief_title":"Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT00574496","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["CD20 • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • cyclophosphamide • ifosfamide • vincristine • vinorelbine tartrate • prednisone • melphalan • fludarabine IV • Matulane (procarbazine hydrochloride) • cyclosporine • Mustargen (mechlorethamine)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/13/2007","start_date":" 11/13/2007","primary_txt":" Primary completion: 08/02/2022","primary_completion_date":" 08/02/2022","study_txt":" Completion: 08/02/2022","study_completion_date":" 08/02/2022","last_update_posted":"2023-09-27"},{"id":"6c8cc15b-7d87-476a-a4ed-393db0c84c6c","acronym":"SHARON","url":"https://clinicaltrials.gov/study/NCT04150042","created_at":"2021-01-18T20:15:45.867Z","updated_at":"2024-07-02T16:35:49.755Z","phase":"Phase 1","brief_title":"SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells","source_id_and_acronym":"NCT04150042 - SHARON","lead_sponsor":"General Oncology, Inc.","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • PALB2 mutation","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carmustine • melphalan • Mustargen (mechlorethamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-04-25"}]